J Med Microbiol Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Erratum for Huang et al., J Med Microbiol 55 (10) 1303-1311.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.
Agricola
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.
J Med Microbiol 56 (2007), 142; DOI:
© 2007 Society for General Microbiology
ISSN 1473-5644

Erratum

A review of an emerging enteric pathogen: enteroaggregative Escherichia coli

David B. Huang, Alakananda Mohanty, Herbert L. DuPont, Pablo C. Okhuysen and Tom Chiang


Journal of Medical Microbiology (2006), 55, part 10, 1303–1311

The second paragraph of the ‘Treatment’ section on page 1308 is incorrect. The correct paragraph is below.

Two clinical trials have been conducted evaluating treatment of EAEC diarrhoea in travellers (Table 5Go). The first trial evaluated the clinical response of travellers with EAEC diarrhoea to ciprofloxacin (500 mg twice a day for 3 days) (Glandt et al., 1999), and the second trial evaluated the clinical response to rifaximin (200 and 400 mg three times a day for 3 days), a poorly absorbed antimicrobial agent (Infante et al., 2004). In the first trial, 29 of 64 (45 %) US travellers to Jamaica and Mexico developed diarrhoea due to EAEC. Sixteen of the patients were treated with ciprofloxacin and 13 with placebo. The patients treated with ciprofloxacin had a significant reduction in the duration of post-treatment diarrhoea (35 versus 56 h), and a non-significant reduction in the mean number of unformed stools passed during the 72 h after enrollment compared to patients who received placebo(six episodes versus eight episodes). The second trial was multicentred, and included 43 of 137 (32 %) US travellers to Guatemala, Kenya and Mexico who developed diarrhoea due to EAEC. Thirty of the patients were treated with rifaximin and 13 with placebo. The patients treated with rifaximin had a significant reduction in the duration of post-treatment diarrhoea compared to placebo (22 versus 72 h).


View this table:
[in this window]
[in a new window]

  		Table 5. Clinical trials evaluating treatment of diarrhoea due to EAEC in travellers

TLUS, time to last unformed stool; NA, not applicable.

 
Some of the information in Table 5Go on page 1309 is incorrect. The correct table is reproduced below.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.
Agricola
Right arrow Articles by Huang, D. B.
Right arrow Articles by Chiang, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS